Guillain-Barré syndrome: a diagnostic and therapeutic update
DOI:
https://doi.org/10.35381/s.v.v8i1.3816Keywords:
Pathology, complications, neurology, (Source: DeCS)Abstract
Objective: To analyze Guillain-Barré syndrome from a documentary review for diagnostic and therapeutic updating. Method: Descriptive documentary review. Conclusion: The first line treatment for Guillain-Barré syndrome is intravenous gamma globulin at a dose of 0.4g/kg for 5 days due to its effectiveness and minimal adverse effects. Plasmapheresis is indicated when treatment with intravenous gamma globulin proves to be ineffective or contraindicated, the combination of both treatments has not shown benefits compared to their individual use, except in severe cases with respiratory failure.
Downloads
References
Shahrizaila N, Lehmann HC, Kuwabara S. Guillain-Barré syndrome. Lancet. 2021;397(10280):1214-1228. https://doi.org/10.1016/S0140-6736(21)00517-1
Leonhard SE, Mandarakas MR, Gondim FAA, et al. Diagnosis and management of Guillain-Barré syndrome in ten steps. Nat Rev Neurol. 2019;15(11):671-683. https://doi.org/10.1038/s41582-019-0250-9
Malek E, Salameh J. Guillain-Barre Syndrome. Semin Neurol. 2019;39(5):589-595. https://doi.org/10.1055/s-0039-1693005
Mirian A, Nicolle MW, Budhram A. Guillain-Barré syndrome. CMAJ. 2021;193(11):E378. https://doi.org/10.1503/cmaj.202710
Sheikh KA. Guillain-Barré Syndrome. Continuum (Minneap Minn). 2020;26(5):1184-1204. https://doi.org/10.1212/CON.0000000000000929
Langille MM. Guillain-Barre Syndrome in Children and Adolescents. Adv Pediatr. 2023;70(1):91-103. https://doi.org/10.1016/j.yapd.2023.04.001
Laman JD, Huizinga R, Boons GJ, Jacobs BC. Guillain-Barré syndrome: expanding the concept of molecular mimicry. Trends Immunol. 2022;43(4):296-308. https://doi.org/10.1016/j.it.2022.02.003
Korinthenberg R, Trollmann R, Felderhoff-Müser U, et al. Diagnosis and treatment of Guillain-Barré Syndrome in childhood and adolescence: An evidence- and consensus-based guideline. Eur J Paediatr Neurol. 2020;25:5-16. https://doi.org/10.1016/j.ejpn.2020.01.003
Magy L, Frachet S. Therapeutic issues in Guillain-Barré syndrome. Expert Rev Neurother. 2023;23(6):549-557. https://doi.org/10.1080/14737175.2023.2212163
Florian IA, Lupan I, Sur L, Samasca G, Timiș TL. To be, or not to be… Guillain-Barré Syndrome. Autoimmun Rev. 2021;20(12):102983. https://doi.org/10.1016/j.autrev.2021.102983
Habib AA, Waheed W. Guillain-Barré Syndrome. Continuum (Minneap Minn). 2023;29(5):1327-1356. https://doi.org/10.1212/CON.0000000000001289
Expósito J, Carrera L, Natera D, Nolasco G, Nascimiento A, Ortez C. Síndrome de Guillain-Barré y otras neuropatías autoinmunes: tratamiento actual [Guillain-Barré syndrome and other autoimmune neurophaties: current therapy]. Medicina (B Aires). 2022;82(Suppl 3):82-88.
Leonhard SE, Cornblath DR, Endtz HP, Sejvar JJ, Jacobs BC. Guillain-Barré syndrome in times of pandemics. J Neurol Neurosurg Psychiatry. 2020;91(10):1027-1029. https://doi.org/10.1136/jnnp-2020-324230
Payus AO, Jan TH, Raymond AA. Guillain-Barré syndrome. Clin Med (Lond). 2020;20(6):e281. https://doi.org/10.7861/clinmed.Let.20.6.6
Busl KM, Fried H, Muehlschlegel S, et al. Guidelines for Neuroprognostication in Adults with Guillain-Barré Syndrome. Neurocrit Care. 2023;38(3):564-583. https://doi.org/10.1007/s12028-023-01707-3
Published
How to Cite
Issue
Section
License
Copyright (c) 2024 John Alexander Valencia-Meléndez, Diego Esteban López-Illescas, Piedad Elizabeth Acurio-Padilla
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.
CC BY-NC-SA : Esta licencia permite a los reutilizadores distribuir, remezclar, adaptar y construir sobre el material en cualquier medio o formato solo con fines no comerciales, y solo siempre y cuando se dé la atribución al creador. Si remezcla, adapta o construye sobre el material, debe licenciar el material modificado bajo términos idénticos.
OAI-PMH: https://fundacionkoinonia.com.ve/ojs/index.php/saludyvida/oai.
